Skip to main content
. 2020 May 18;123(3):378–391. doi: 10.1038/s41416-020-0891-x

Fig. 3. CDK4/6 inhibition enhances cisplatin efficacy in cisplatin-resistant and -sensitive GCT cells.

Fig. 3

XTT data of cisplatin-resistant and -sensitive GCT cell lines 2102EP(-R) and NT27D1(-R) treated once with palbociclib (5 μM), ribociclib (15 μM) or cisplatin (5/2.5 μM) alone and in combination. Changes in viability (compared to solvent-treated controls) were measured over 96 h.